About PatentCliff

Why pharmaceutical patent data deserves a public-facing home

The FDA Orange Book and USPTO patent records together constitute the public record of every U.S. pharmaceutical patent. The data covers brand-name drug patents, the expiration dates that drive generic-launch timing, and the patent challenges that can shift the timeline. This information is publicly available across two federal systems with very different presentation conventions; assembling the patent picture for a specific drug or company requires cross-referencing both, which is more friction than most users are willing to accept.

PatentCliff consolidates the picture. Every drug page shows the active patents, the projected expiration dates, and the generic-launch timeline. Every company page rolls up the patent portfolio. Every grade page groups drugs by the time horizon until patent expiration. The data is what the federal government already publishes; the value the site adds is the cross-reference between the Orange Book and the USPTO record.

How the pipeline pulls FDA and USPTO data

The FDA Orange Book pulls run quarterly when FDA publishes the updated Orange Book file. USPTO pulls run continuously to capture new patent grants and challenges. Each drug record is cross-referenced between the two sources to produce the patent-expiration timeline shown on the per-drug pages.

A practical detail: the patent-expiration date is the earliest unencumbered date for generic launch under current patent law, but real-world generic launches depend on additional factors — patent challenges, paragraph IV certifications, and FDA approval of the generic application. The expiration date is a necessary but not sufficient condition for generic entry; the pages flag drugs with known patent challenges.

Where pharmaceutical patent data has caveats

Three caveats. First, the Orange Book lists patents that the brand-name manufacturer has identified as covering the drug. Other patents may exist — process patents, formulation patents — that are not in the Orange Book but can still affect generic-launch timing. For full patent due diligence, the Orange Book is the starting point, not the comprehensive list.

Second, biologic drugs follow a different exclusivity regime (the Biologics Price Competition and Innovation Act) rather than the Orange Book / Hatch-Waxman framework that covers small-molecule drugs. The site focuses on small-molecule drugs; the biologics calendar is a separate analysis.

Third, generic-launch timing depends on FDA approval of the specific generic application, which has its own queue and review timeline. Patent expiration sets the earliest possible launch date; the actual launch can lag by months or years on the generic manufacturer’s filing schedule, and the FDA’s queue depth for the specific generic application. Every page on the site links back to the originating federal dataset for verification; readers using the data for decisions should always cross-reference the most recent source release rather than treating any site value as the final word. Federal data products are continuously revised, and the live source is always the right reference for time-sensitive decisions. The methodology page on this site documents every dataset, every refresh cadence, and every limitation in detail so readers can trace any numeric value on the site back to the underlying federal source. We treat that traceability as a hard requirement for any data product that asks readers to make real-world decisions on its output. depending on the generic manufacturer’s filing schedule.